The oncolytic virus renaissance: improving the efficacy of current immunotherapies Oncolytics Biotech Inc. featured in the pharmphorum’s Deep Dive on Oncology Pharma companies are turning to oncolytic viruses to increase … Continue reading “Oncolytics Biotech: The oncolytic virus renaissance: improving the efficacy of current immunotherapies”
Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, … Continue reading “Silence Therapeutics Technology Licensee Quark Pharmaceuticals announces First Patient Dosed in Phase 3 Clinical Trial for Acute Kidney Injury”
Turku, Finland, July 4 2018: Forendo Pharma, a drug development company focusing on novel oral treatments for endometriosis patients, today announces it has received clinical trial authorisation (CTA) from the … Continue reading “Forendo Pharma initiates phase I study for potential new, targeted treatment for endometriosis”
The majority of the questions in this LSX survey are multiple choice, therefore it should take you no longer than 10 minutes to complete. LSX C-Suite Survey Please note that … Continue reading “The LSX C-Suite Challenges in Life Sciences Survey 2018”
Hamburg, Germany, 18 June 2018: Evotec AG today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec … Continue reading “Evotec and Sanofi sign definitive agreement to combat infectious diseases”
HASSELT, Belgium and CHEPSTOW, Wales, April 16, 2018 /PRNewswire/ — Phase I data show early efficacy in the majority of patients and a very favourable safety profile Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific … Continue reading “Apitope Announces Positive Results with Novel Treatment for Graves’ Disease”
11 April 2018, Windsor, UK: Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation small molecules aiming to modulate immune responses to combat cancer and other … Continue reading “Macrophage Pharma appoints Dr Michael Moore as Chairman”
Bionical Clinical EAP is the first and only global specialist Early Access Program partner that harnesses the full power of an established and successful Clinical Research Organization whilst applying a deep … Continue reading “Bionical Group Ltd today announces the launch of Bionical-Clinical early access programs (EAP)”
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced that it has won the Life Science Innovation Award at the Business … Continue reading “STORM Therapeutics wins Life Science Innovation Award”
New investor survey highlights need for companies to significantly step up their investor communications 21 March 2018, London, UK: Optimum Strategic Communications (Optimum), the international strategic healthcare communications firm, today … Continue reading “Life Sciences Investors Concerned Over Corporate Readiness for MIFID II”
HASSELT, Belgium, and CHEPSTOW, UK, 19 March 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced publication of data on it multiple … Continue reading “Apitope Announces Publication of Data in International Peer-Reviewed Journal Neurology on Novel Multiple Sclerosis Therapy”
Turku, Finland, March 19th, 2018: Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces that it has been granted a €3 million R&D loan … Continue reading “Forendo Pharma recieves €3 million loan from business Finland to develop novel treatments for Endometriosis”
vasopharm GmbH, a privately held biopharmaceutical company, today announced that it has recruited half of the 220 patients in the ongoing, pivotal European NOSTRA III (NO Synthase in TRAumatic Brain … Continue reading “Vasopharm provides update on phase iii traumatic brain injury trial”
COPENHAGEN, Denmark— 12 March 2018 Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces it has … Continue reading “Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation”
Hamburg, Germany; Paris, France, 08 March 2018 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research … Continue reading “Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform”
HASSELT, Belgium, and CHEPSTOW, UK, 7th March 2018 Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced the appointment of William Jenkins, M.D., … Continue reading “Dr William Jenkins appointed as Independent Non-Executive Director Recent board roles include Ablynx, BTG, Evotec”
Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors. Read … Continue reading “David Colpman joins the Board of Directors of Forendo Pharma”
Significantly Expands Number of Healthcare Clients Since Launch 02 March 2018, London: Optimum Strategic Communications (Optimum), an international strategic healthcare communications and investor relations advisor, announces its appointment as investor … Continue reading “Optimum Appointed by Silence Therapeutics as Financial PR and Investor Relations Advisor in Europe & US”
Appoints Internationally Renowned Scientific Advisors COPENHAGEN, Denmark— 8 February 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common … Continue reading “Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2018 Optimum Strategic Communications All rights reserved.
9 Devonshire Square
London
EC2M 4YF
Tel: +44 (0)203 714 1788
Email: [email protected]